Study to Evaluate the Efficacy and Safety of Tilpisertib in Adults With Moderately to Severely Active Ulcerative Colitis

Summary

The primary objective of this study is to demonstrate the efficacy of tilpisertib (formerly GS-4875) compared with placebo control in achieving clinical remission per modified Mayo Clinic Score (MCS) in adults with moderately to severely active ulcerative colitis (UC).

Timeline

Start

2019-12-20

Primary completion

2021-02-25

Completion

2021-12-14

Outcome

Outcome not reported

Stopped: “Sponsor terminated the study since a new molecular entity was able to achieve greater target coverage”

Drugs

Indications